Kelly Coverdale on LinkedIn: What are some of the most important considerations for MedTech start-ups… (2024)

Fueling Precision Medicine Ventures with Smart InvestmentsSecuring the right financing is crucial for precision medicine startups. Explore the role of venture capital, public markets, and government partnerships in advancing groundbreaking therapies. Understand the challenges and opportunities in this dynamic field and how strategic investments can lead to better healthcare solutions. 📈 #InvestingInHealthcare #PrecisionMedicine #FundingInnovation

1

📣📣📣Applications are open for the next Medtech Accelerator program in partnership with incredible industry leaders - Baxter International Inc., GE HealthCare, and Endeavor Health. 8 to 10 teams will be selected to receive 💵 $142.5K cash investment to support the advancement of their technology and growth of their company. Plus over two years of support and access to mHUB - the nation's leading hardtech incubator and manufacturing entrepreneurship company - and the opportunity to secure an additional $300K+ in funding from industry partners for underwriting trials, investment, etc.Apply today by visiting - https://lnkd.in/gkxDh57UWe are seeking the top companies from around the world creating unique market opportunities across:💡Robotic or automated healthcare devices💡Chronic disease management tools💡Connected therapeutic devices💡Surgical instruments💡Detect acute or chronic conditions💡Minimally invasive monitoring💡Medical Devices💡Improve drug delivery methodsDM me if you have questions or would like to connect with the programs Executive Director Monica Vajani and mHUB Ventures Managing Partner Melissa Rabin Lederer or a current portfolio company.#hardtech #medtech #entreprenuership #accelerator #venture #impacthumanity

89

2 Comments

2024: a year of Biotech Insane MegaroundsHas capital efficiency as a concept only left to be followed by faint hearted execs Or Big funds by virtue can only deploy massive dough to hand picked untrodden ideas- Historically, Small rounds used to be 65% of the total financings in any given yr - & Megarounds used to be 14% of any given year financings - In 2024: 58% of total VC dollars gone into merely 25 companies in a form of MegaroundsWhy Megarounds: - Big funds have to deploy big cheques (fund optics)- Supporting vision stories or sometimes companies with real assets- Funding to "clinical PoC" value inflection- More crossoves coming early - Multiple shots on goal for companies - IPO window closingWhat Megrounds would mean: - Definitely: Good for building drug development talent - Maybe: Good for better medicines - Less likely: Good for returns(60% of the recent Life Sci capital raised is controlled by 20% of the funds)

147

8 Comments

The Global Digital Therapeutics (DTx) Investors Directory 2Q 2024 provides a comprehensive overview of the key investors who are actively funding and supporting the growth of DTx startups across various health conditions. This directory is an invaluable resource for understanding the landscape of investment in digital health technologies, showcasing the diverse range of investors and their portfolios. Each entry includes brief information about the investors' focus areas, investment strategies, and the specific DTx startups they support, highlighting their commitment to advancing innovative solutions in healthcare.This directory spans a wide array of health conditions, including mental health, cognitive health, neurological health, and chronic conditions, among others. It offers insights into the strategic interests of different investors, from early-stage venture capital firms to large global investment groups. By profiling the investors and their investee companies, the directory illustrates the dynamic ecosystem of digital therapeutics and the critical role of financial backing in bringing cutting-edge health technologies to market. This resource serves as a crucial tool for startups seeking investment, stakeholders in the digital health space, and anyone interested in the trends and developments shaping the future of digital therapeutics.#digitaltherapeutics #dtx #HealthTechInvestment #VentureCapital #digitalhealth #StartupFunding #startup #fundraising

15

1 Comment

As this article notes, Medical Alley partner Endogenex has a lot to celebrate. The company's $88 million raise in June is the largest health technology financing deal this year. Companies in Medical Alley successfully raised $334 million in private capital in Q2. That's more than double the amount raised in Q1.While market activity is up, we know many of our emerging organizations are still struggling.The journey ahead requires continued dedication to innovation to keep this growth moving forward.“The increase in private capital and mergers and acquisition activity in the second quarter is a promising sign that the market is beginning to recover,” said Roberta Antoine Dressen, chief executive of Medical Alley,said in a recent Star-Tribune article. “We must continue to attract funding to sustain this momentum.”Read more here – https://lnkd.in/eJKXjKW2

13

Fund-Raised Global Digital Therapeutics (DTx) Startups - Investors Mapping Through an extensive search and review of publicly available information, 172 startups were selected for detailed analysis regarding their fundraising status. Among these, 94 Digital Therapeutics (DTx) startups have collectively raised $6.859 billion from global investors. These startups include Raft Digital Therapeutics, Mindable Health GmbH, MicroHealth, Vigo Health, SleepUp, Vitadio s.r.o., Neurolief, OPTT Health, Vivira Health, XR Therapeutics, and many others. They are supported by a diverse range of investors, such as aMoon Fund, Expansion Capital, UV-Cap, 7wireVentures, Accelmed Partners, Adage Capital Management, and BCG Digital Ventures, among others. This substantial funding highlights the growing investor confidence and interest in DTx innovations.#dtx #digitaltherapeutics #startup #vc #funding #fundraising #investment

11

2 Comments

📈 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗙𝘂𝗻𝗱𝗿𝗮𝗶𝘀𝗶𝗻𝗴 𝗥𝗲𝗮𝗰𝗵𝗲𝘀 𝗧𝘄𝗼-𝗬𝗲𝗮𝗿 𝗛𝗶𝗴𝗵 𝗶𝗻 𝗤𝟮 𝟮𝟬𝟮𝟰! 📈Great news for the biotech sector! Privately held drug developers raised an impressive $6.7 billion in Q2, marking the strongest fundraising quarter since early 2022. This surge, highlighted in William Blair's latest quarterly analysis, signals a promising rebound for the industry after several challenging years.However, it's not all smooth sailing. Investors are becoming increasingly selective. According to Oppenheimer, biotech VC firms are flocking to the most compelling stories, resulting in longer deal closures due to elevated investor selectivity and rigorous due diligence.𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀• Total Fundraising: Hit a two-year peak with an average of $94 million per financing round.• Megarounds: At least 27 in Q2, though this frenzy is expected to cool in H2.• Crossover Rounds: 14 rounds from April to June, the best period since Q3 2021.Kevin Eisele of William Blair's healthcare equity capital markets team noted, "This is an encouraging sign that the market broadly is reopening." With multiple biotechs in the IPO queue, the momentum seems poised to continue. This uptick is not just a flash in the pan. For the first time since 2021, we’ve seen at least 10 biotech crossover financings in two consecutive quarters. Looking forward, several biotechs like Artiva, Aprinoia, and Actuate are lined up for IPOs, with others potentially following post-Labor Day.🌟 Exciting times ahead for biotech financing and IPOs!Information and picture taken from this article: https://lnkd.in/eJ55zWvp#Biotech #Fundraising #VentureCapital #IPO #HealthcareInnovation #InvestmentTrends #Biotechnology

18

🚨 Key Takeaways from Life Sciences Pennsylvania Future event 🚨- 70% of VC dollars invested in Life Sciences don’t return the initial investment.- Only 9% of VC investments result in a 2X return.- 44% of Americans will face some form of mental illness, yet only 9% of pharmaceutical drugs target this critical issue.The need for smaller VC firms (with funds in the $20-30M range) is crucial—they can provide the $2M checks that startups need to get off the ground, which are too small for bigger firms. One of the biggest hurdles to getting products to the next level are Clinical trials and cost. This is what we have heard from others, and I’d love to hear your thoughts and ideas. My key takeaway: life-saving ideas are out there, but too many of them go to the grave without the right funding!How do we get these startups help? #LifeSciences #Startups #VC #HealthcareInnovation #MentalHealth #LetsTalk #raredisease

10

A fantastic opening pitch from our CEO Tanya Aneichyk at Techstars investor day!Did you know that $4Billion was spent on data licensing deals last year alone? But the process is incredibly inefficient and flawed. OmicsChart is building a solution to address this and save thousand of hours for pharma. Get in touch with us to hear the full pitch! #startups #investment #funding #biotech #healthtech #techbio #computationalbiology #cancerresearch #vcfund

30

3 Comments

I highly recommend this talk- innovation done well:

6